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This study estimated the risk of second primary malignancies after Hodgkin’s lymphoma (HL) in relation to family history of cancer,
age at diagnosis and latency, among 6946 patients treated for HL in Sweden in 1965–1995 identified through the Swedish Cancer
Register (SCR). First-degree relatives (FDRs) to the HL patients and their malignancies were then ascertained together with their
malignancies through the Multi-Generation Registry and SCR. The HL patient cohort was stratified on the number of FDRs with
cancer, and standardised incidence ratios (SIRs) of developing SM were analysed. In the HL cohort, 781 SM were observed 1 year or
longer after HL diagnosis. The risk for developing SM increased with the number of FDRs with cancer, SIRs being 2.26, 3.01, and 3.45
with 0, 1, or X2 FDRs with cancer, respectively. Hodgkin’s lymphoma long-term survivors treated at a young age with a family history
of cancer carry an increased risk for developing SM and may represent a subgroup where standardised screening for the most
common cancer sites could be offered in a stringent surveillance programme.
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The proportion of long-term survivors following Hodgkin’s
lymphoma (HL) has increased since the mid-twentieth century
(Devita et al, 1970; Jenkin et al, 1990; Fuchs et al, 2006). Long-term
survivors of HL have a shorter life expectancy compared with the
normal population, since they have a significantly elevated risk
of developing second malignancies (SMs), heart diseases, lung
diseases, and infections; SM being the commonest cause of death
(Mauch, 1996; Hoppe, 1997; Swerdlow et al, 2000; Dores et al, 2002;
Foss Abrahamsen et al, 2002; Ng et al, 2002; Aleman et al, 2003).
The incidence of SM increase especially after 10 years latency and
among patients treated below the age of 40 years, in which
radiotherapy has been suggested as the main underlying factor.
Haematological malignancies develop earlier, within the first 10
years after treatment, probably due to the chemotherapy and not
radiotherapy (Kaldor et al, 1990). It is not established in long-term
follow-up if the frequency of SM is reduced with lower doses of
radiation and reduced target fields (Franklin et al, 2005).
In the present study, we estimated the standardised incidence
ratio (SIR) for SM in the Swedish population with HL diagnosed in
Sweden in 1965–1995 and in relation to family history of cancer.
PATIENTS AND METHODS
By law since 1958, all malignancies in Sweden must be reported to
the Swedish Cancer Register (SCR), at the National Board of Health
and Welfare. From this register, 6946 HL cases diagnosed in
1965–1995 were identified. Early in this period, extended field
irradiation, mainly mantle field, was the standard treatment.
Patients received radiotherapy, chemotherapy or a combination of
both. Details of disease extent, therapy or its results are not
registered in the SCR, and nor on different HL subtypes. There
were 2873 female and 4073 male patients, with mean age at
diagnosis of 52 years. Date and cause of death were obtained by
matching the cohort to the Cause of Death Register, which was
updated until 31 December 2004.
In the HL cohort, 1993 were alive at the end of 2004 and among
the 4953 deceased, the mean age at death was 65 years; 2311
individuals died within the first year after diagnosis. Among the
2642 who died 1 year or later after HL diagnosis, 570 (21.3 %) died
with the occurrence of SM during the follow-up, with a mean age
of death of 65.8 years. Characteristics of the patients are shown in
Table 1. The patients were observed until 31 December 2004, time
of migration from Sweden or death, whichever came first and
linked to SCR for SM. The date of occurrence of a new malignancy
and the site of origin were registered. The first year after HL
diagnosis was omitted because of the likelihood of excess cases
being due to increased surveillance (Thellenberg et al, 2003).
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multiplying the person-years for every calendar year, sex, and
5-year age group by the corresponding age-specific incidence rate
in Sweden. The SIR was calculated by dividing the observed
number of cases by the number expected (Breslow and Day, 1980).
The risk was estimated 1–9, 10–19, and X20 years after treatment
of HL with a 95% confidence interval (CI).
We also investigated whether a familial history of cancer further
increased the risk of SM after HL. From the Multi-Generation
Registry at Statistics, Sweden, (MGR), first-degree relatives (FDRs)
to our cohort of the initial 6946 HL patients were collected. First-
degree relatives include parents, siblings, and children. Because the
MGR includes parents for children born after 1932, full nuclear
families are not available for all patients in the HL cohort. If a
person died before 1961, he might be lost by follow-up (Hemminki
et al, 2001). In this register, there were 17858 FDRs to the HL
cohort, who were then matched to the SCR to determine their
cancer incidence, and hence the family history of cancer for each
HL patient was then calculated. The cohort of relatives was
compared with the normal population in Sweden to estimate the
cancer SIRs. Finally, SIRs were calculated in the HL cohort for SM
when stratified for having 0, 1, or X2 relatives with cancer. The
absolute excess risk was calculated as the observed number of SMs
in our cohort minus that expected divided by the number of
person-years at risk multiplied by 10000.
RESULTS
Survival in HL patients treated for HL at 40 years or younger was
decreased compared with the general Swedish population, and also
10 years or more after treatment (Figure 1). Even the relative
survival – matched for age, sex, and year – was decreased. Of the
6946 HL patients, 4623 survived more than 1 year after diagnosis
and of these 696 (15%) developed a total of 781 SMs. Solid tumours
accounted for 645 (82.6%) of these and haematological malig-
nancies for 136 (17.4%). The SIR for SM overall was significantly
increased, at 2.62 (95% CI: 2.32–2.96) 10–19 years after HL
diagnosis (Table 2). When stratified for age at HL diagnosis,
incidence was especially increased among those diagnosed before
the age of 40 years, SIR 4.34 (95% CI: 3.51–5.30).
One of the commonest SM was breast cancer with risk increased
10–19 years after HL only seen in the group treated before the age
of 40 years, SIR 5.20 (95% CI: 3.39–7.62), compared with those
aged 40 years or older, SIR 1.23 (95% CI: 0.56–2.34). Other
common cancers overrepresented were lung, SIR 3.26 (95% CI:
2.09–4.85) and colorectal cancers, SIR 2.42 (95% CI: 1.60–3.49)
(Table 2). In the cohort of 17858 FDRs, there were 4440 parents,
4611 siblings, and 8807 children. There was no increased risk for
developing cancer overall in the cohort of relatives compared with
the general population, SIR 1.01 (95% CI: 0.97–1.05).
In the HL cohort, 1453 individuals (20.9%) had one or more
FDRs with cancer. There was a gradually increased risk for SM
with the number of FDRs with cancer, one SIR 3.01 (2.57–3.51)
and two or more SIRs 3.45 (2.58–4.51) (Table 3).
The risks of breast, lung, and colorectal cancers stratified for the
number of FDRs with cancer overall were calculated, initially on 0,
1, or 2 or more FDRs, but as there were no obvious trends and the
numbers were small, the analyses simply considered positive or
negative family history of cancer. The risk for breast cancer was
increased with a positive family history of cancer, especially after
420 years follow-up, SIR 5.52 (3.32–8.62) (Table 4). For all HL
patients with a family history of lung cancer, there seems to be an
especially increased risk of lung cancer X10 years after treatment
of HL. No corresponding increased risk of breast cancer with a
family history of breast cancer was observed.
DISCUSSION
Risk of SM was especially increased in young patients with a family
history of cancer and a long follow-up. This could indicate a
gene–environment or environment–environment interaction, as
recently proposed in other studies of cohorts exposed to ionising
radiation (Flint-Richter and Sadetzki, 2007). Strengths of the
present study are the mean follow-up of 12.3 years (range: 0–38
years) and that the SCR is known to be complete and nationwide,
thereby excluding underreporting (Frodin et al, 1997; Sandblom
et al, 2003).
Our data do not suggest that a family history of breast cancer
adds to the risk of secondary breast cancer. In another study
increasing doses of RT did not add to the risk of breast cancer in
the presence of a positive family history of breast or ovarian cancer
in first- or second-degree relatives (Hill et al, 2005).
A novel observation was an increased risk of lung cancer in HL
patients with a family history of lung cancer, which might be due
to genetic or environmental causes such as smoking habits;
although details of these were not available in this study.
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Figure 1 Absolute and relative survival for HL patients treated before
the age of 40 years between the years of 1965 and 1995 compared with
the normal population in Sweden.
Table 1 Characteristics of the Hodgkin’s lymphoma patients and their
first-degree relatives
Characteristics
Number of patients, total 6946
Male 4073
Female 2873
Mean age at diagnosis, years (range) 52 (2–100)
Mean age o40 years at diagnose, n 2379
o40 years at diagnosis and alive at the end of 2004, n 1558
Diagnosis year, range 1965–1995
Number of deceased 4953
Mean age at death, years (range) 65 (7–100)
Number of patients with follow-up X1 year 4623
Mean follow-up (years)
a
All 12.3 (0–38)
Alive at the end of follow-up 19.0 (8–38)
First-degree relatives 17858
b
Parents 4440
Siblings 4611
Offspring 8807
aCalculated for individuals with a follow-up X1 year.
b17798 unique individuals.
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survivors, although here family history of cancer was collected
using patient interviews and medical records and not system-
atically from a cancer register (Nichols et al, 1999). Only one large
study has investigated the family history of cancer overall in
relation to SM risk after lymphoma, including HL (Landgren et al,
2007). The 7476 HL cases studied from Sweden and Denmark with
a shorter follow-up partly overlapped with our study. Their study
showed an increased risk for breast cancer, RR 1.81 (95% CI: 1.04–
3.16) in the HL subgroup with a positive family history of cancer.
Whereas they estimated risks with Cox proportional hazard ratios,
we used a comparison to the general population. We omitted the
Table 2 Risk for second cancer overall and cancer at the most common sites, 1–9, 10–19 and 20 years or over after HL, for all ages and o40 years at
HL treatment
Year after treatment
1–9 10–19 20
     N N N 1
     N N N
Site O SIR (95% CI) O SIR (95% CI) O SIR (95% CI) O E/SIR (95% CI)
Treated for HL at all ages
Cancer overall 349 2.39 (2.14–2.65) 265 2.62 (2.32–2.96) 167 2.44 (2.08–2.84) 781 2.48 (2.30–2.65)
Breast 15 0.98 (0.55–1.61) 35 2.84 (1.98–3.95) 31 3.52 (2.39–5.00) 81 2.22 (1.76–2.76)
Colorectal 37 2.94 (2.06–4.04) 28 2.42 (1.60–3.49) 17 2.21 (1.28–3.53) 82 2.57 (2.04–3.19)
Kidney 4 0.89 (0.23–2.16) 5 1.73 (0.56–4.04) 4 2.32 (0.62–5.93) 13 1.39 (0.73–2.37)
Leukaemia
a 38 6.61 (4.67–9.07) 10 2.67 (1.28–4.91) 9 3.57 (1.62–6.78) 57 4.75 (3.59–6.14)
Lung 31 2.83 (1.92–4.01) 24 3.26 (2.09–4.85) 27 5.40 (3.56–7.86) 82 3.59 (2.85–4.46)
NHL 36 8.59 (6.02–11.90) 26 8.34 (5.44–12.22) 14 6.67 (3.64–11.19) 76 8.08 (6.36–10.10)
Pancreas 5 1.11 (0.36–2.59) 8 3.12 (1.34–6.14) 8 5.40 (2.32–10.64) 21 2.45 (1.51–3.75)
Prostate 32 1.54 (1.05–2.17) 20 1.30 (0.79–2.00) 9 0.73 (0.33–1.38) 61 1.25 (0.95–1.61)
Skin
b 39 6.70 (4.76–9.15) 28 5.93 (3.94–8.58) 11 3.01 (1.50–5.39) 78 5.50 (4.34–6.86)
Thyroid 5 3.98 (1.28–9.28) 8 9.99 (4.30–19.68) 2 4.99 (0.56–18.03) 15 6.10 (3.41–10.05)
Treated for HLoage 40 years
Cancer overall 58 4.66 (3.54–6.03) 96 4.34 (3.51–5.30) 119 3.60 (2.98–4.31) 273 4.03 (3.56–4.53)
Breast 3 1.36 (0.27–3.97) 26 5.20 (3.39–7.62) 27 4.55 (2.99–6.61) 56 4.22 (3.19–5.48)
Colorectal 2 2.70 (0.30–9.76) 5 3.09 (0.99–7.21) 12 3.86 (1.99–6.74) 19 3.54 (2.12–5.52)
Kidney 0 — 3 5.56 (1.11–16.23) 2 2.33 (0.26–8.39) 5 3.01 (0.97–7.02)
Leukaemia
a 17 30.91 (17.99–49.49) 6 5.13 (1.87–5.13) 1 0.88 (0.01–4.92) 24 8.42 (5.39–12.53)
Lung 2 5.26 (0.59–19.00) 2 1.68 (0.18–6.07) 22 8.91 (5.57–14.49) 26 6.44 (4.20–9.43)
NHL 8 16.67 (7.17–32.84) 10 12.5 (5.98–22.99) 10 9.62 (4.60–17.68) 28 12.02 (7.98–17.36)
Pancreas 0 — 1 3.03 (0.03–16.86) 6 9.52 (3.47–20.73) 7 6.48 (2.59–13.35)
Prostate 0 — 1 1.47 (0.01–8.18) 4 0.86 (0.23–2.21) 5 0.94 (0.30–2.18)
Skin
b 1 4.55 (00.59–25.29) 6 12.00 (4.38–26.12) 7 7.00 (2.80–14.42) 14 8.05 (4.39–13.50)
Thyroid 2 4.88 (0.54–17.61) 6 14.29 (5.21–31.09) 2 7.69 (0.86–27.77) 10 9.01 (4.31–16.56)
Treated for HLX age 40 year
Cancer overall 291 2.18 (1.93–2.45) 169 2.14 (1.83–2.49) 48 1.36 (1.00–1.80) 508 2.05 (1.87–2.23)
Breast 12 0.92 (0.48–2.18) 9 1.23 (0.52–2.34) 4 1.48 (0.40–3.78) 25 1.08 (0.70–1.59)
CI¼confidence interval; HL¼Hodgkin’s lymphoma; MDS¼myelodysplastic syndromes; NHL¼nonHodgkin’s lymphoma; SIR¼standardised incidence ratio. For cancer overall
and breast cancer, the risk has also been calculated among individuals treated at the age of 40 years or older.
aThe group Leukaemia includes MDS, myeloma, lymphatic
leukaemia, myeloic leukaemia, monocytic leukaemia, and leukaemia UNS.
bIC7 191. Malignant melanomas excluded.
Table 3 Risk for second cancer overall after HL at any age and before the age of 40 years stratified on the number of first-degree relatives with cancer
overall
Number of first-degree relatives with cancer overall
01 2 o r 42
Age at treatment Years, after HL O SIR (95% CI) O SIR (95% CI) O SIR (95% CI)
All ages X1 561 2.26 (2.08–2.45) 167 3.01 (2.57–3.51) 53 3.45 (2.58–4.51)
All ages 1–9 284 2.31 (2.05–2.59) 54 2.74 (2.06–3.57) 11 2.58 (1.29–4.62)
10–19 185 2.39 (2.06–2.76) 57 2.99 (2.27–3.88) 23 4.15 (2.63–6.23)
X20 92 1.92 (1.55–2.36) 56 3.37 (2.54–4.37) 19 3.41 (2.05–5.33)
o40 years X1 141 3.78 (3.18–4.46) 101 4.35 (3.54–5.28) 39 4.35 (3.09–5.95)
o40 years 1–9 37 4.84 (3.41–6.68) 15 3.75 (2.10–6.19) 6 4.41 (1.61–9.60)
10–19 47 3.85 (2.83–5.12) 35 4.69 (3.26–6.52) 14 4.91 (2.68–8.24)
X20 52 2.97 (2.22–3.89) 48 4.06 (3.00–5.39) 19 3.98 (2.40–6.22)
CI¼confidence interval; HL¼Hodgkin’s lymphoma; SIR¼standardised incidence ratio. Hodgkin diagnoses.
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increased surveillance. The present study indicates that cancer
among FDRs gives an additional increase to SM risk among HL
survivors. There was also a trend of increased risk of SM with the
numbers of relatives with malignancies, although there were few
with two or more relatives with cancer.
A surveillance programme for women treated with radiotherapy
for HL has proposed investigation with the same standard as other
groups of women at higher risk for breast cancer (Dershaw et al,
1992; Wolden et al, 2000, Diller et al, 2002, Faulkner and Law,
2005). An increased risk of secondary lung cancer has been
reported (Metayer et al, 2000; Foss Abrahamsen et al, 2002), while
chemotherapy and radiotherapy were associated with an elevated
risk of lung cancer as an SM further increased by smoking habits
up to 20-fold (Travis et al, 2002). We also found lung cancer risk
increasing from 10 years after treatment, seeming to increase
continuously thereafter, particularly in men (Table 2). An
environmental interaction of radiotherapy and smoking can be
suspected. Increased risk in the first 10 years could be due to
chemotherapy or the increased numbers of computed tomography
(CT) scans for detecting smaller tumours during HL follow-up.
There is no good evidence that screening with CT of the lung will
have any cost benefit in nonsmokers, although larger studies are
necessary to address this question (Das et al, 2006). There is no
obvious pattern of decreased SM risk after a certain number years
except for breast cancer.
A drawback of the study is that the Swedish Cancer Register holds
no therapy data, but studies have shown that up to 90% of patients
were given radiotherapy during our study period (Glimelius et al,
1994, Molin et al, 2003). Many HL patients were probably diagnosed
as nonHodgkin’s lymphoma (NHL), but because most of them were
older patients with a short survival, this will not affect the present
results, especially those with long follow-up that are compared with
the general population. It might, however, influence overall survival
as prognosis is generally poorer for NHL.
The high curability of HL has increased the number of long-term
survivors (Fuchs et al, 2006). In our cohort of 2000 HL survivors,
most were treated with extended radiation field. A Swedish pilot
study (unpublished) indicates that only about 60% of these
patients have regular clinic visits. Women over 40 years of age
participate in the general mammography screening programme.
The Swedish HL Group currently offers patients who are not
participating in regular clinic visits a standardised surveillance
programme. The goal is to find SM at an earlier stage and thereby
raise the cure rate. Mammography and ultrasound will be offered
to women treated before the age of 40 years. Patients with
gastrointestinal or pulmonary symptoms will be offered a
radiological examination. The importance of smoking cessation
is stressed and patients will be offered referral to smoking
cessation programmes.
Our study indicates that SM incidence is increased among the
long-term HL survivors with a family history of cancer, young age
of onset, and long latency, perhaps reflecting gene–environment
interactions; this could be relevant in future surveillance
programmes.
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